Literature DB >> 15871732

Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.

Maurits M Barendrecht1, Richard P Koopmans, Jean J M C H de la Rosette, Martin C Michel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15871732     DOI： 10.1111/j.1464-410X.2005.05487.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  13 in total

Review 1.  Acute urinary retention: who is at risk and how best to manage it?

Authors:  Anand Patel; Christopher Chapple
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 2.  Benign prostatic hyperplasia: treatment in primary care.

Authors:  Anand K Patel; Christopher R Chapple
Journal:  BMJ       Date:  2006-09-09

Review 3.  [Drug-drug interactions in urology].

Authors:  M C Michel; R F Schäfers; J J M C H de la Rosette
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 4.  [Importance of adrenoceptor blockers and alpha reductase inhibitors : Monotherapy for treatment of benign prostate syndrome].

Authors:  F Strittmatter; S Madersbacher; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

5.  [Medical therapy of lower urinary tract symptoms [corrected]].

Authors:  F Strittmatter; S Madersbacher; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2012-08       Impact factor: 0.639

Review 6.  Effects of alpha(1)-adrenoceptor antagonists on male sexual function.

Authors:  Marleen M van Dijk; Jean J M C H de la Rosette; Martin C Michel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro.

Authors:  Jia-an Sun; De-zhi Kong; Ya-qin Zhen; Qing Li; Wei Zhang; Jiang-hua Zhang; Zhi-wei Yin; Lei-ming Ren
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

8.  Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study.

Authors:  Hyo Serk Lee; Sae Woong Kim; Seung-June Oh; Myung-Soo Choo; Kyu-Sung Lee
Journal:  Korean J Urol       Date:  2012-03-19

9.  Various treatment options for benign prostatic hyperplasia: A current update.

Authors:  Alankar Shrivastava; Vipin B Gupta
Journal:  J Midlife Health       Date:  2012-01

10.  Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.

Authors:  Mischel G Neill; Rohan Shahani; Alexandre R Zlotta
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.